Diagnostic, Pharmaceutical and Radiopharmaceuticals

Telix acquires assets targeting FAP in nuclear medicine

AuntMinnie

NOVEMBER 20, 2024

Telix Pharmaceuticals is expanding its theranostic pipeline with newly acquired assets targeting fibroblast activation protein (FAP) in nuclear medicine. FAP is a pan-cancer marker expressed in the tumor microenvironment of epithelial cancers and on the surface of some specific cancer types, including sarcomas and mesotheliomas.

Nuclear Medicine

Nuclear Medicine Pharmaceutical Radiopharmaceuticals Clinic

Blue Earth Diagnostics inks Posluma deal with Sinotau Pharmaceutical

AuntMinnie

OCTOBER 17, 2023

Blue Earth Diagnostics and Sinotau Pharmaceutical have signed an agreement to distribute Blue Earth's Posluma (flotufolastat F-18) PET radiotracer in China.

Pharmaceutical

Pharmaceutical Diagnostic Radiopharmaceuticals

RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers

Imaging Technology

SEPTEMBER 20, 2023

a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.

Pharmaceutical

Pharmaceutical Radiopharmaceuticals Radiation Diagnostic

The rise of theranostics: Part 5 -- Advice from center administrators

AuntMinnie

JULY 12, 2024

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. At the time, their cancer center served a significant cancer population in the region and maintained robust and ever-expanding PET diagnostics.

Nuclear Medicine

Nuclear Medicine Radiation Oncology Radiopharmaceuticals Radiation

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology

FDA fast-tracks Clarity’s prostate cancer treatment

AuntMinnie

FEBRUARY 19, 2025

Clarity Pharmaceuticals has secured fast-track designation from the U.S. Food and Drug Administration (FDA) for its copper-67 (Cu-67) SAR-bisPSMA radiopharmaceutical for treating advanced prostate cancer.

Radiopharmaceuticals

Radiopharmaceuticals Pharmaceutical Disease Diagnostic Imaging

Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer

Imaging Technology

JULY 9, 2024

Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Board of Directors.

Diagnostic

Diagnostic Radiopharmaceuticals Nuclear Medicine Magnetic Resonance Imaging

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Radiopharmaceuticals

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan

Clarity, PSI enter agreement on phase III of SAR-bisPSMA trial

AuntMinnie

OCTOBER 25, 2023

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, and PSI CRO, a global contract research organization, plan to conduct a trial using Clarity's phase III diagnostic trial of Clarify for prostate cancer patients.

Pharmaceutical

Pharmaceutical Radiopharmaceuticals Diagnostic Clinic

Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Imaging Technology

JULY 25, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals

Radiopharmaceuticals Imaging Pharmaceutical Disease

Telix to buy RLS Radiopharmacies in $250M agreement

AuntMinnie

SEPTEMBER 22, 2024

Telix Pharmaceuticals has inked a deal to acquire Florida-based radiopharmacy network RLS Radiopharmacies for up to $250 million, the companies announced. and distributes PET, SPECT, and therapeutic radiopharmaceuticals through 31 radiopharmacies across 18 states, Telix said. “By

Radiopharmaceuticals

Radiopharmaceuticals Pharmaceutical Diagnostic IT

First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Imaging Technology

JULY 11, 2023

We are delighted by our collaboration with Ratio Therapeutics in advancing the clinical development of RTX-1363S as a FAP-targeted diagnostic to the clinic," stated Etienne Montagut, Lantheus' Chief Business Officer. "By milla1cf Tue, 07/11/2023 - 09:02 July 11, 2023 — Ratio Therapeutics Inc.

Radiopharmaceuticals

Radiopharmaceuticals Imaging Pharmaceutical Disease

NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production

Imaging Technology

JULY 25, 2024

Medical isotopes are essential for a wide range of diagnostic and therapeutic procedures, including cancer treatments and advanced imaging techniques. This agreement could be instrumental to the radiopharmaceutical industry and patient health. a subsidiary of BWX Technologies, Inc.

Medical

Medical Radiopharmaceuticals Pharmaceutical Clinic

SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

Imaging Technology

OCTOBER 11, 2023

based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). milla1cf Wed, 10/11/2023 - 13:24 October 11, 2023 — GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based

Healthcare

Healthcare Healthcare Pharmaceutical Radiopharmaceuticals

NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations

Imaging Technology

APRIL 24, 2023

milla1cf Mon, 04/24/2023 - 14:10 April 24, 2023 — - NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the appointment of Jean-Noel David , MBA, MS, as Vice President, Operations.

Medical

Medical Radiopharmaceuticals Pharmaceutical Government

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

APRIL 3, 2023

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors

Imaging Technology

JANUARY 5, 2024

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.

Radiopharmaceuticals

Radiopharmaceuticals Medical Nuclear Medicine Pharmaceutical

GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

Imaging Technology

NOVEMBER 2, 2023

After regional regulatory approvals, GE HealthCare plans to commercialize the models for use both in pharmaceutical drug development and for clinical decision support. The company recently announced the first patient scanned in a Phase I clinical trial of a first-of-its kind fluorine-18 PET radiopharmaceutical specific for CD8.

Healthcare

Healthcare Healthcare Pharmaceutical Clinic

GE HealthCare Closes MIM Software Acquisition

Imaging Technology

APRIL 2, 2024

announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio.

Healthcare

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging

Diagnostic Imaging Brief

Telix acquires assets targeting FAP in nuclear medicine

Blue Earth Diagnostics inks Posluma deal with Sinotau Pharmaceutical

Trending Sources

RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers

The rise of theranostics: Part 5 -- Advice from center administrators

The rise of theranostics: Part 3 -- What is a theranostics center?

FDA fast-tracks Clarity’s prostate cancer treatment

Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

Clarity, PSI enter agreement on phase III of SAR-bisPSMA trial

Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Telix to buy RLS Radiopharmacies in $250M agreement

First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production

SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors

GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

GE HealthCare Closes MIM Software Acquisition

Stay Connected